Previous 10 | Next 10 |
TEL AVIV, Israel , July 30, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended June 30, 2019 on Tuesday, August ...
The board of BioLineRx (NASDAQ: BLRX ) has approved a change in its ADS/ordinary share ratio from 1:1 to 1:15, in essence, a reverse split of the ADSs. More news on: BioLineRx Ltd., Healthcare stocks news, Stocks on the move, Read more ...
TEL AVIV, Israel , June 28, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depos...
TEL AVIV, Israel , June 13, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, Philip Serlin , will present a company update at the JMP Securitie...
BioLineRx Ltd. (BLRX) Q1 2019 Results Earnings Conference Call May 14, 2019, 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Phil Serlin - CEO Mali Zeevi - CFO Abi Vainstein - VP, Clinical Development Ella Sorani - VP, Research and Development Conferen...
TEL AVIV, Israel , May 14, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended March 31, 2019 and provided a corporate update. Highlights and achieve...
TEL AVIV, Israel , May 7, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended March 31, 2019 on Tuesday, May 14, ...
TEL AVIV, Israel , May 7, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application...
NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on BioLineRx Ltd. (NASDAQ: BLRX) is a clinical stage biopharmaceutical development ...
BioLineRx Ltd. (BLRX) Q4 2018 Earnings Conference Call March 27, 2019, 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Phil Serlin - CEO Mali Zeevi - CFO Abi Vainstein - VP, Clinical and Medical Affairs Ella Sorani - VP, Research and Development Confer...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...